Compare Semaglutide vs Tirzepatide: Evidence-Based Choice
Wegovy Semaglutide vs Mounjaro: Understanding the Key Differences
When comparing Wegovy semaglutide to Mounjaro, the fundamental difference lies in their mechanisms of action and clinical development pathways. Wegovy semaglutide works as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and blood sugar levels, while Mounjaro's tirzepatide targets both GIP and GLP-1 receptors for a dual approach to weight management. Both prescription-only medicines require clinical assessment and ongoing monitoring through a qualified healthcare provider.
The dosing schedules also differ significantly between these treatments. Wegovy semaglutide follows a structured 5-dose escalation from 0.25mg to the maintenance dose of 2.4mg over 17 weeks, whilst Mounjaro tirzepatide offers 6 dose levels from 2.5mg up to 15mg. This difference in dosing flexibility means your prescriber will consider your individual tolerance and response when recommending the most suitable option for your weight management journey.
Wegovy Semaglutide Pricing and Value at EverydayMeds
Our transparent pricing structure for Wegovy semaglutide starts with single pens from £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers can apply discount code FIRST40 at checkout, while returning patients use code DOSE25 to access these competitive prices. Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99.
When comparing value between Wegovy semaglutide and Mounjaro, consider not just the upfront cost but also the practical benefits and storage advantages. Both treatments are available through EverydayMeds with the same rigorous clinical assessment process, next-day cold-chain delivery, and ongoing prescriber support. Our clinical team can help you understand the cost implications of each treatment pathway during your consultation.
Clinical Evidence for Wegovy Semaglutide: STEP Trial Results
The STEP clinical trial programme provides robust evidence for Wegovy semaglutide's effectiveness in weight management. In the landmark STEP 1 trial, participants taking Wegovy semaglutide alongside diet and exercise achieved an average weight reduction of approximately 15% at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of 15.2% at 2 years, while the SELECT cardiovascular outcomes study showed a 20% reduction in major cardiovascular events.
It's important to note that individual results may vary, and these clinical trial outcomes represent averages across diverse study populations. Both Wegovy semaglutide and Mounjaro have demonstrated significant weight loss potential in their respective clinical programmes, though direct head-to-head comparisons are limited due to different trial designs and patient populations studied.
How Wegovy Semaglutide Works: GLP-1 Mechanism Explained
Wegovy semaglutide functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestines. This mechanism may help reduce appetite by acting on brain centres that control hunger and satiety, potentially leading to smaller portion sizes and reduced food cravings. The weekly injection provides sustained hormone activity, offering consistent appetite regulation throughout the treatment period. Unlike rapid-acting appetite suppressants, Wegovy semaglutide works gradually to support sustainable eating pattern changes. The treatment must be combined with a reduced-calorie diet and increased physical activity to achieve optimal results, as demonstrated in clinical trials.
Ordering Wegovy Semaglutide: Streamlined Online Process
Our ordering process for Wegovy semaglutide begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. A qualified prescriber reviews your application within 3 working days (or 24 hours with express service), ensuring the treatment is clinically appropriate for your circumstances. Once approved, your Wegovy semaglutide pen is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all dispensing meets UK regulatory standards. You'll receive detailed injection instructions, dose escalation guidance, and ongoing support throughout your treatment journey.
Storage and Practical Considerations for Wegovy Semaglutide
Wegovy semaglutide requires refrigeration at 2-8°C before first use but offers a significant practical advantage with 6 weeks of room temperature stability below 30°C once removed from the fridge. This extended room temperature tolerance makes Wegovy particularly suitable for travel or flexible lifestyle schedules, compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen system provides precise dose delivery with an easy-to-use design suitable for weekly self-injection. Dose escalation is mandatory and cannot be rushed, allowing your body to adapt gradually to the medication. Each pen contains a single dose, eliminating guesswork and ensuring accurate dosing throughout your treatment programme.
Wegovy Semaglutide vs Mounjaro: Storage and Convenience Comparison
The practical differences between Wegovy semaglutide and Mounjaro extend beyond their biological mechanisms to real-world convenience factors. Wegovy's 6-week room temperature stability provides nearly three times the flexibility of Mounjaro's 21-day limit, making it more suitable for frequent travellers or those with unpredictable schedules. Both treatments require weekly injections, but the dose escalation patterns differ significantly in duration and complexity.
Patient preference often comes down to individual factors such as injection experience, side effect profiles, and lifestyle considerations. Your prescriber will consider these practical elements alongside clinical factors when recommending between Wegovy semaglutide and Mounjaro. Both treatments are available through EverydayMeds with identical service standards, allowing you to focus on the clinical suitability rather than supply chain concerns.
Making Your Choice: Wegovy Semaglutide Treatment Support
Selecting between Wegovy semaglutide and Mounjaro should be based on clinical assessment rather than assumptions about effectiveness or convenience. Both treatments require commitment to lifestyle modifications and regular monitoring for optimal results. Our clinical team provides ongoing support throughout your treatment journey, including dose adjustment guidance and side effect management. Remember to apply discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout to access our competitive pricing. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and discover which treatment option aligns with your weight management goals and lifestyle requirements.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
